Jenscare Scientific Co., Ltd.

Jenscare Scientific Co., Ltd. (stock code: 9877.HK, referred to as "Jenscare") was established in 2011. The company is headquartered in Ningbo, China, with branches in Beijing, Shanghai, Wuhan, Hainan Free Trade Port, Hong Kong, and Netherlands. Jenscare has independently developed a series of innovative minimally invasive interventional medical devices in the field of structural heart disease to fulfill the large but underpenetrated market. Covering tricuspid valve disease, mitral valve disease, aortic valve disease, heart failure and cardioembolic thrombi prevention, Jenscare has a comprehensive and advanced product portfolio for structural heart diseases. One of the core products, Lux-Valve Transcatheter Tricuspid Valve Replacement System, is expected to be one of the first TTVR products approved for commercialization globally.